Advertisement
U.S. Markets closed

Novogene Co., Ltd. (688315.SS)

Shanghai - Shanghai Delayed Price. Currency in CNY
12.88-0.15 (-1.15%)
At close: 03:00PM CST

Novogene Co., Ltd.

Building 301
Zone A10 Jiuxianqiao North Road Chaoyang District
Beijing
China
86 10 8283 7801
https://www.novogene.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 2,144

Key Executives

NameTitlePayExercisedYear Born
Dr. Ruiqiang LiFounder, Chairman of the Board & CEON/AN/A1980
Mr. Yang YuDeputy General ManagerN/AN/A1985
Ms. Yanping LiDeputy General ManagerN/AN/A1977
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CNY.

Description

Novogene Co., Ltd. provides genomic services and solutions worldwide. The company offers genomic solutions, such as human genome sequencing, gene regulation, single cell sequencing, animal and plant solutions, and microbial genome sequencing; and cancer genomic profiling, whole exome sequencing, and FFPE RNA sequencing, as well as clinical-grade whole exome sequencing services. It also provides NovoFocus CR, a gene coverage for hereditary cancer screening; and NovoNeoantigen, a bioinformatics pipeline for the identification of cancer neoantigens with whole exome sequencing and whole transcriptome sequencing data from paired tumor-normal samples. The company was founded in 2011 and is headquartered in Beijing, China.

Corporate Governance

Novogene Co., Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.